



ASX Announcement

February 28th 2023

Significant Purchase Order for HIV Self-Tests for Europe

SYDNEY, Australia, February 28th, 2023 - Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to announce it has secured a purchase order from UK based diagnostics company Newfoundland Diagnostics Limited (Newfoundland), worth approximately A\$900,000. The order is for immediate supply of Atomo's product to Newfoundland, subject to updating Atomo's existing HIV Self-Test CE certificate to include the relevant distributor information and branding.

Newfoundland is an emerging leader in the growing European diagnostic self-test market that has arisen out of the COVID pandemic and has established extensive distribution networks in Europe across public health, pharmacy and retail channels. Atomo and Newfoundland anticipate that this purchase order for HIV Self-Tests will be the first of many and are currently working to rapidly conclude a comprehensive agreement for supply of Atomo's award-winning HIV products to Newfoundland for Europe.

Atomo's CEO John Kelly said "We are delighted to have received this initial order from Newfoundland. They have a strong track record in accessing leading retail channels and supplying tests to the UK and European markets. We believe they are an ideal commercial partner for our HIV products as well as potentially a range of other at-home tests that we are looking to commercialise".

Mr Kelly added, "We are seeing an increase in HIV sales volume globally and now expect to see a significant growth in the European market with this new commercial relationship. These developed healthcare markets offer significantly improved margins when compared to our global health HIV business and will continue to be a key focus for us as we seek to diversify our sales across different markets to achieve volume and margin improvements".



Newfoundland CEO, Mr Frederick Manduca said, “We have been impressed with Atomo’s user friendly products that improve ease of use for the home test market and we are keen to work with Atomo to see Newfoundland further establish itself as a leader in the supply of best-in-class rapid test products in Europe”.

Atomo has terminated the HIV distribution agreement covering the UK and other European markets previously entered into with Owen Mumford Limited. The appointment of an alternative distributor once completed will be disclosed in due course.

For more information, please contact:

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnositics.com
Phone: +61 401 922 279

This announcement was authorised by the Managing Director & CEO.

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, COVID-19, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at www.atomodiagnositics.com